Oncology Survivorship Care — Part 4: Psychosocial Health, Sexual Dysfunction, and Health Promotion
Depression, anxiety, PTSD, fear of recurrence, sexual health, physical activity, nutrition, smoking cessation, alcohol, sun protection, and immunizations for cancer survivors.
1. Psychosocial Health in Cancer Survivors
1.1 Prevalence and Importance
Psychosocial distress affects a substantial proportion of cancer survivors and can persist for years after treatment completion. Untreated psychological distress impairs quality of life, adherence to surveillance and health-promoting behaviors, functional capacity, and may even adversely affect cancer outcomes. All survivorship care guidelines recommend routine screening for psychosocial distress as a standard component of care.1 2
Prevalence of Psychosocial Conditions in Cancer Survivors
| Condition | Estimated Prevalence |
|---|---|
| Clinically significant distress | 20–40% |
| Depression (major depressive disorder) | 8–20% (vs. 5–8% general population) |
| Anxiety disorders | 15–25% |
| Post-traumatic stress disorder (PTSD) | 5–15% |
| Fear of cancer recurrence (clinically significant) | 30–70% report some level; 15–20% report severe, functionally impairing fear |
| Adjustment disorders | 15–30% |
| Sleep disturbance | 30–60% |
1.2 Screening for Psychosocial Distress
Screening should be performed at the survivorship transition visit, at regular intervals during follow-up (at least annually), and at any time of clinical transition or heightened vulnerability (e.g., around surveillance imaging, anniversary dates of diagnosis).1
Recommended Screening Tools
| Domain | Tool | Scoring / Threshold |
|---|---|---|
| Overall distress | Distress Thermometer (DT) | 0–10 scale; score ≥4 indicates clinically significant distress requiring further assessment |
| Depression | Patient Health Questionnaire-9 (PHQ-9) | Score ≥10 suggests moderate depression; ≥15 suggests moderately severe to severe depression |
| Anxiety | Generalized Anxiety Disorder-7 (GAD-7) | Score ≥10 suggests moderate anxiety; ≥15 suggests severe anxiety |
| PTSD | PTSD Checklist for DSM-5 (PCL-5); Primary Care PTSD Screen (PC-PTSD-5) | PCL-5 score ≥31–33 suggests probable PTSD; PC-PTSD-5 score ≥3 of 5 triggers referral |
| Fear of recurrence | Fear of Cancer Recurrence Inventory (FCRI); Cancer Worry Scale (CWS) | FCRI severity subscale ≥13 suggests clinically significant fear of recurrence |
| Insomnia | Insomnia Severity Index (ISI) | Score ≥10 suggests clinical insomnia; ≥15 suggests moderate-severe insomnia |
1.3 Depression and Anxiety — Management
| Intervention | Details |
|---|---|
| Psychotherapy | Cognitive-behavioral therapy (CBT) is the best-studied intervention for depression and anxiety in cancer survivors; interpersonal therapy (IPT) and problem-solving therapy are also effective; should be offered as first-line for mild to moderate symptoms |
| Pharmacotherapy for depression | SSRIs (sertraline, citalopram, escitalopram) or SNRIs (venlafaxine, duloxetine) are first-line; duloxetine preferred when concurrent neuropathic pain or fatigue; avoid paroxetine and fluoxetine in patients on tamoxifen (CYP2D6 inhibition reduces tamoxifen efficacy); mirtazapine useful when insomnia and poor appetite are prominent; bupropion appropriate when fatigue is dominant |
| Pharmacotherapy for anxiety | SSRIs/SNRIs as first-line; buspirone for generalized anxiety; benzodiazepines only for short-term use due to dependence risk and cognitive effects; hydroxyzine as alternative short-term anxiolytic |
| Exercise | Strong evidence for reduction of depressive and anxious symptoms; should be recommended as adjunct to all survivors |
| Mindfulness-based stress reduction (MBSR) | 8-week structured program with demonstrated efficacy for distress, anxiety, and depression in cancer survivors |
Tamoxifen Drug Interaction Considerations
| CYP2D6 Inhibitor Strength | Antidepressants to AVOID with Tamoxifen | Safe Alternatives |
|---|---|---|
| Strong inhibitors (contraindicated) | Paroxetine, fluoxetine | — |
| Moderate inhibitors (use with caution) | Bupropion, duloxetine | — |
| Weak/no interaction (preferred) | — | Venlafaxine (preferred), citalopram, escitalopram, sertraline, desvenlafaxine |
1.4 Post-Traumatic Stress Disorder (PTSD)
Cancer-related PTSD can develop in response to the cancer diagnosis, treatment experiences (particularly ICU stays, invasive procedures, life-threatening complications), or the threat of recurrence. Treatment follows standard PTSD evidence-based approaches:
| Intervention | Details |
|---|---|
| Trauma-focused CBT | First-line psychotherapy for PTSD; includes cognitive processing therapy (CPT) and prolonged exposure (PE) |
| EMDR (Eye Movement Desensitization and Reprocessing) | Alternative evidence-based psychotherapy for PTSD |
| Pharmacotherapy | SSRIs (sertraline, paroxetine) are first-line pharmacotherapy for PTSD; venlafaxine as alternative; prazosin (1–15 mg at bedtime) for PTSD-related nightmares |
1.5 Fear of Cancer Recurrence (FCR)
Fear of cancer recurrence is one of the most common unmet needs in cancer survivorship. While some degree of vigilance is adaptive, clinically significant FCR is characterized by high levels of preoccupation, hypervigilance to bodily sensations, excessive reassurance-seeking, functional impairment, and avoidance behaviors (such as avoiding surveillance appointments).3
Interventions for FCR
| Intervention | Evidence |
|---|---|
| ConquerFear (metacognitive therapy–based intervention) | RCT evidence showing reduction in FCR; addresses attentional bias, metacognitive beliefs about worry, and values-based goal setting |
| CBT-based interventions | Multiple RCTs support CBT approaches for FCR |
| Acceptance and commitment therapy (ACT) | Emerging evidence for FCR; focuses on acceptance of uncertainty and values-based living |
| Mindfulness-based interventions | Moderate evidence for reduction in FCR |
| Psychoeducation | Normalizing fear while providing realistic recurrence risk information; helpful but insufficient alone for severe FCR |
2. Sexual Health and Dysfunction
2.1 Overview
Sexual dysfunction is highly prevalent among cancer survivors, affecting 30–80% of patients depending on the cancer type, treatment modality, and measurement methods used. Despite this prevalence, sexual health remains underaddressed in survivorship care. Clinicians should proactively screen for sexual concerns and offer evidence-based interventions or referral.4
2.2 Common Sexual Health Problems by Cancer Type and Treatment
| Cancer / Treatment | Sexual Health Concerns |
|---|---|
| Breast cancer (surgery, chemotherapy, endocrine therapy, radiation) | Decreased libido; vaginal dryness and dyspareunia (especially with aromatase inhibitors); body image disturbance; premature menopause; loss of sensation in reconstructed breast |
| Prostate cancer (prostatectomy, radiation, ADT) | Erectile dysfunction (60–90% post-prostatectomy; 30–50% post-radiation); decreased libido and anorgasmia with ADT; penile shortening; urinary incontinence affecting intimacy; altered ejaculation |
| Gynecologic cancers (surgery, radiation, chemotherapy) | Vaginal stenosis and shortening (post-radiation); vaginal dryness; dyspareunia; premature menopause; body image changes; loss of fertility-related grief |
| Colorectal cancer (surgery, radiation) | Erectile and ejaculatory dysfunction (post-pelvic surgery, especially APR); dyspareunia; stoma-related body image concerns; pelvic radiation effects |
| Hematologic cancers (chemotherapy, TBI, transplant) | Gonadal failure; GVHD-related genital symptoms in women (vaginal dryness, stenosis, pain); fatigue-related decreased desire |
| Head and neck cancer | Body image and self-esteem changes; difficulty with intimacy due to facial disfigurement, tracheostomy, feeding tubes; xerostomia affecting kissing |
2.3 Assessment
- Sexual health should be assessed as part of routine survivorship care. The PLISSIT model (Permission, Limited Information, Specific Suggestions, Intensive Therapy) provides a framework for addressing sexual concerns.
- Validated tools: Female Sexual Function Index (FSFI); International Index of Erectile Function (IIEF); Patient-Reported Outcomes Measurement Information System (PROMIS) Sexual Function and Satisfaction measures.
- Assess contributing medications (antidepressants, opioids, antihypertensives, endocrine therapies).
2.4 Management
Female Sexual Dysfunction
| Problem | Interventions |
|---|---|
| Vaginal dryness / dyspareunia | Non-hormonal vaginal moisturizers (hyaluronic acid–based; polycarbophil-based, e.g., Replens) — regular use 2–3×/week; water- or silicone-based lubricants during intercourse; vaginal dilators (particularly post-radiation) — begin 2–4 weeks after radiation completion, use 3–5×/week |
| Vaginal atrophy (if hormonal treatment permissible) | Low-dose vaginal estrogen (estradiol vaginal tablet 10 mcg; estradiol vaginal ring 7.5 mcg/24h) — minimal systemic absorption; generally considered acceptable even in breast cancer survivors after discussion of risks/benefits with oncologist; vaginal DHEA (prasterone 6.5 mg intravaginal nightly) — FDA-approved for dyspareunia; does not significantly raise systemic estrogen |
| Decreased libido | Assess and treat contributing factors (depression, fatigue, pain, body image, relationship distress); consider referral to sexual health specialist or sex therapist; testosterone therapy is not routinely recommended for female cancer survivors due to limited evidence and hormonal concerns |
| Pelvic floor dysfunction | Pelvic floor physical therapy for dyspareunia, vaginismus, pelvic pain; referral to specialized pelvic floor physiotherapist |
Male Sexual Dysfunction
| Problem | Interventions |
|---|---|
| Erectile dysfunction (post-prostatectomy) | Penile rehabilitation: PDE5 inhibitors (sildenafil 25–100 mg, tadalafil 5–20 mg) — may begin as early as nerve-sparing surgery recovery; vacuum erection devices; intracavernosal injection therapy (alprostadil, trimix); penile prosthesis for refractory ED |
| Erectile dysfunction (post-radiation) | PDE5 inhibitors (first-line); onset of radiation-related ED may be delayed 6–24 months post-treatment; same escalation pathway as above |
| Erectile dysfunction (ADT-related) | PDE5 inhibitors less effective during active ADT (low libido limits benefit); testosterone recovery monitoring after ADT cessation; supportive counseling |
| Decreased libido (ADT-related) | Expected during ADT; improves after testosterone recovery; couples counseling; explore non-coital intimacy |
| Ejaculatory dysfunction | Retrograde ejaculation (post-RPLND, post-prostatectomy); anejaculation — counsel about fertility implications; supportive counseling |
General Approaches
| Intervention | Details |
|---|---|
| Psychosexual counseling / sex therapy | Recommended for persistent sexual difficulties, body image disturbance, and relationship strain; couples therapy may be particularly beneficial |
| Body image interventions | CBT-based body image programs; peer support groups; post-mastectomy/reconstruction support |
| Fertility-related grief counseling | For survivors who desired future childbearing and have treatment-induced infertility |
3. Health Promotion in Cancer Survivors
3.1 Physical Activity
Physical activity is one of the most evidence-supported health-promoting interventions in cancer survivorship, with demonstrated benefits for fatigue, physical function, quality of life, anxiety, depression, body composition, cardiovascular risk, bone health, and possibly cancer recurrence and overall survival.5 6
Recommended Physical Activity Levels
| Component | Recommendation |
|---|---|
| Aerobic exercise | At least 150 minutes/week of moderate-intensity (e.g., brisk walking, cycling, swimming) OR 75 minutes/week of vigorous-intensity aerobic exercise; can be accumulated in bouts of ≥10 minutes |
| Resistance training | At least 2 sessions/week involving major muscle groups; begin with low resistance and progress gradually; particularly important for survivors at risk for sarcopenia, osteoporosis, and those who received corticosteroids or ADT |
| Flexibility and balance | Stretching exercises after each session; balance exercises (yoga, tai chi) recommended for survivors with neuropathy or at risk for falls |
| Progression | Survivors who are deconditioned should begin with low-intensity, short-duration activity and gradually increase; supervised exercise programs are preferred for the first 8–12 weeks, particularly in those with significant deconditioning or comorbidities |
Specific Considerations by Functional Status
| Status | Approach |
|---|---|
| Fully functional (ECOG 0) | Meet general population physical activity guidelines; encourage structured exercise programs |
| Mildly limited (ECOG 1) | Individualized program; may need modified intensity; emphasize consistency over intensity |
| Limited self-care (ECOG 2) | Focus on maintaining function; gentle aerobic activity (walking), seated exercises, light resistance bands; physical therapy referral |
| Ostomy patients | Exercise is safe and encouraged; stoma protection during resistance training; swimming is safe with appropriate appliance |
| Lymphedema risk or active lymphedema | Exercise with fitted compression garment; progressive resistance training is safe and does not worsen lymphedema; begin gradually |
| Neuropathy (CIPN) | Balance training; fall prevention; supervised exercise recommended; aquatic exercise may be beneficial |
| Bone metastases (stable) | Avoid high-impact loading of affected areas; adapted resistance training under supervision; physical therapy guidance |
Pre-Exercise Screening
- Cancer survivors should be assessed for contraindications before beginning an exercise program: uncontrolled cardiac disease, symptomatic anemia, active infection, unstable bone metastases, severe thrombocytopenia, and severe neutropenia.
- Exercise tolerance testing (cardiopulmonary exercise testing) recommended for survivors with known or suspected cardiovascular disease before initiating vigorous exercise.
3.2 Nutrition and Weight Management
Healthy body weight and dietary patterns are associated with reduced risk of cancer recurrence, second primary cancers, cardiovascular disease, and all-cause mortality in cancer survivors.5
Weight Management Recommendations
| Situation | Recommendation |
|---|---|
| Overweight or obese survivors (BMI ≥25) | Aim for gradual weight loss (0.5–1 kg/week) through caloric reduction and increased physical activity; evidence supports reduced cancer recurrence risk with weight normalization, particularly in breast and colorectal cancer |
| Underweight or sarcopenic survivors | Nutritional assessment and optimization; high-protein diet (1.2–1.5 g/kg/day); resistance exercise to increase lean mass; dietitian referral |
| Weight gain on endocrine therapy (AI, ADT) | Proactive counseling about expected weight gain; early exercise and dietary intervention; monitor for metabolic syndrome |
Dietary Recommendations
| Recommendation | Details |
|---|---|
| Emphasize plant-based foods | ≥5 servings of fruits and vegetables daily; whole grains over refined grains; legumes as protein sources |
| Limit red and processed meat | Red meat ≤3 servings/week; minimize processed meats (associated with colorectal cancer risk) |
| Limit added sugars and ultra-processed foods | Associated with obesity, metabolic syndrome, and potentially increased cancer risk |
| Adequate protein intake | 1.0–1.5 g/kg/day, particularly important during and after treatment to maintain lean mass |
| Limit saturated fat | <10% of total calories; replace with unsaturated fats (olive oil, nuts, fatty fish) |
| Calcium and vitamin D | Ensure adequate intake for bone health (calcium 1,000–1,200 mg/day; vitamin D ≥600–1,000 IU/day; supplement as needed) |
| Fiber | 25–30 g/day; associated with reduced colorectal cancer risk and improved metabolic health |
| Alcohol | See section 3.4 below |
| Supplements | No evidence supports routine use of high-dose vitamin or antioxidant supplements for cancer prevention in survivors; may be harmful in some settings; supplement only documented deficiencies |
3.3 Smoking Cessation
Continued tobacco use after cancer diagnosis is associated with increased all-cause mortality, cancer-specific mortality, risk of second primary cancers, increased treatment toxicity, and impaired wound healing. Smoking cessation is critical in all survivors.7
Approach to Smoking Cessation in Cancer Survivors
| Component | Details |
|---|---|
| Assessment | Ask about tobacco use at every visit; document current status, amount, and readiness to quit |
| Brief intervention (5 A’s) | Ask, Advise (clear, personalized advice to quit), Assess (willingness to attempt), Assist (provide pharmacotherapy and counseling), Arrange (follow-up within 1–2 weeks) |
| Pharmacotherapy | Varenicline (1 mg BID after 1-week titration): most effective single agent; OR bupropion SR (150 mg BID): also treats depression; OR nicotine replacement therapy (NRT): patch, gum, lozenge, inhaler, nasal spray; combination therapy (patch + short-acting NRT, or varenicline + NRT) more effective than monotherapy |
| Behavioral counseling | Individual, group, or telephone counseling; quitline referral (1-800-QUIT-NOW in the US); CBT-based approaches; digital health tools and apps |
| Special considerations | E-cigarettes: not recommended as a cessation aid by major oncology societies; safety data in cancer survivors insufficient; head and neck cancer survivors: particularly important given aerodigestive second primary risk; lung cancer survivors: reduces second primary risk and cardiovascular morbidity |
3.4 Alcohol Moderation
Alcohol consumption is an established risk factor for cancers of the breast, head and neck, esophagus, liver, and colorectum. Even moderate alcohol intake is associated with increased breast cancer risk and recurrence.5
| Recommendation | Details |
|---|---|
| Cancer survivors should limit or avoid alcohol | If consumed, limit to ≤1 drink/day for women and ≤2 drinks/day for men (1 drink = 14 g alcohol = 12 oz beer, 5 oz wine, 1.5 oz spirits) |
| Breast cancer survivors | Evidence suggests avoiding alcohol or limiting to <3 drinks/week; even moderate intake may increase recurrence risk |
| Head and neck cancer survivors | Abstinence is strongly recommended; synergistic risk with tobacco for second primary aerodigestive cancers |
| Hepatocellular carcinoma survivors | Abstinence is mandatory |
| Colorectal cancer survivors | Limit alcohol; associated with increased second primary risk |
3.5 Sun Protection
Cancer survivors — particularly those with a history of radiation therapy, immunosuppression, or prior skin cancer — are at increased risk for skin cancers. All survivors should follow sun-protective behaviors.2
| Recommendation | Details |
|---|---|
| Sunscreen | Broad-spectrum SPF ≥30; apply 15–30 minutes before sun exposure; reapply every 2 hours and after swimming or sweating |
| Protective clothing | Wide-brimmed hats, long sleeves, UPF-rated clothing |
| Avoid peak UV hours | Avoid direct sun exposure between 10 AM and 4 PM when feasible |
| Avoid tanning beds | Particularly important for immunosuppressed survivors and those with radiation exposure history |
| Skin self-examination | Monthly self-examinations; report new or changing lesions promptly |
| Professional skin examination | Annual full-body skin examination by a dermatologist for high-risk survivors (prior radiation, immunosuppression, transplant recipients, prior skin cancer) |
3.6 Immunizations for Cancer Survivors
Cancer survivors may have impaired immune function due to prior chemotherapy, radiation, immunotherapy, splenectomy, or ongoing immunosuppressive therapy. Vaccination recommendations differ from the general population in important ways.8
General Principles
- Live vaccines are contraindicated in immunosuppressed patients. Immune reconstitution sufficient for live vaccines typically requires ≥3 months (some guidelines suggest ≥6 months) after completion of cytotoxic chemotherapy and ≥6 months after anti-CD20 antibody therapy (rituximab).
- Inactivated vaccines are safe in immunocompromised patients but may be less immunogenic; administer when feasible.
- Revaccination should be considered after completion of intensive chemotherapy or stem cell transplant, as treatment may eliminate prior vaccine immunity.
Vaccination Schedule for Cancer Survivors
| Vaccine | Recommendation |
|---|---|
| Influenza (inactivated) | Annual inactivated influenza vaccine for all cancer survivors; live attenuated influenza vaccine (LAIV/FluMist) contraindicated in immunocompromised patients; household contacts should also receive annual influenza vaccination (inactivated preferred) |
| COVID-19 | Per current public health guidance; additional doses may be recommended for immunocompromised individuals |
| Pneumococcal | PCV20 (pneumococcal conjugate vaccine 20-valent) as a single dose if not previously vaccinated; OR PCV15 followed by PPSV23 at least 8 weeks later; administer ≥2 weeks before planned chemotherapy if feasible |
| Hepatitis B | Complete series if not previously immune; check anti-HBs titer after series completion; additional dose if non-responder |
| Herpes zoster (shingles) | Recombinant zoster vaccine (RZV, Shingrix) — non-live, safe in immunocompromised patients ≥19 years old who are or will be immunodeficient; recommended for adults ≥50 or immunocompromised ≥19; administer ≥6 months after completion of cytotoxic therapy when feasible |
| HPV | Complete series for survivors aged 9–26 (or through age 45 via shared clinical decision-making) if not previously completed; particularly relevant for survivors of HPV-related cancers and those with prior immunosuppression |
| Tetanus/diphtheria/pertussis (Tdap/Td) | Per general population guidelines; Tdap booster once, then Td every 10 years |
| Meningococcal | For asplenic patients (functional or surgical) or complement-deficient: MenACWY and MenB series with boosters per guidelines |
| Haemophilus influenzae type b (Hib) | For asplenic patients: 1 dose if not previously vaccinated |
Stem Cell Transplant Recipients — Special Vaccination Schedule
Stem cell transplant (SCT) recipients require revaccination starting approximately 3–6 months post-transplant, as prior immunity is typically lost. A detailed revaccination schedule should be coordinated with the transplant team. Key points:
- Begin inactivated vaccines (pneumococcal, Hib, DTaP, hepatitis B, inactivated polio, influenza) at 3–6 months post-transplant.
- Live vaccines (MMR, varicella) generally deferred until ≥24 months post-transplant and ≥12 months off immunosuppressive therapy, and only if no active GVHD.
- Recombinant zoster vaccine (Shingrix) can be given starting at 3–6 months post-transplant.
- Household contacts should have all recommended vaccinations current, including annual influenza.
4. Summary Table: Health Promotion Interventions
| Domain | Recommendation | Strength of Evidence |
|---|---|---|
| Physical activity | ≥150 min/week moderate aerobic + 2×/week resistance training | Strong |
| Weight management | Maintain healthy BMI (18.5–24.9); achieve gradual weight loss if overweight/obese | Strong |
| Diet | Plant-based emphasis; limit red/processed meat, added sugars; adequate protein, fiber, calcium, vitamin D | Moderate |
| Smoking cessation | Assess at every visit; offer pharmacotherapy + counseling | Strong |
| Alcohol | Limit or avoid; ≤1 drink/day women, ≤2 drinks/day men; abstinence for high-risk cancers | Moderate to Strong |
| Sun protection | Sunscreen, protective clothing, avoid tanning; annual skin exam for high-risk | Moderate |
| Immunizations | Annual influenza; pneumococcal; zoster (RZV); HPV completion; per guidelines for immunocompromised | Strong |
References
Recklitis CJ, Syrjala KL. “Provision of Integrated Psychosocial Services for Cancer Survivors Post-Treatment.” Lancet Oncology, 18(1): e39–e50, 2017. ↩︎ ↩︎
Denlinger CS, Sanft T, Moslehi JJ, et al. “NCCN Clinical Practice Guidelines in Oncology: Survivorship.” Version 1.2024. National Comprehensive Cancer Network (NCCN). ↩︎ ↩︎
Lebel S, Ozakinci G, Humphris G, et al. “From Normal Response to Clinical Problem: Definition and Clinical Features of Fear of Cancer Recurrence.” Supportive Care in Cancer, 24(8): 3265–3268, 2016. ↩︎
Carter J, Lacchetti C, Andersen BL, et al. “Interventions to Address Sexual Problems in People with Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline.” Journal of Clinical Oncology, 36(5): 492–511, 2018. American Society of Clinical Oncology (ASCO). ↩︎
Rock CL, Thomson CA, Sullivan KR, et al. “American Cancer Society Nutrition and Physical Activity Guideline for Cancer Survivors.” CA: A Cancer Journal for Clinicians, 72(3): 230–262, 2022. American Cancer Society (ACS). ↩︎ ↩︎ ↩︎
Campbell KL, Winters-Stone KM, Wiskemann J, et al. “Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable.” Medicine and Science in Sports and Exercise, 51(11): 2375–2390, 2019. ↩︎
US Department of Health and Human Services. “Smoking Cessation: A Report of the Surgeon General.” 2020. ↩︎
Rubin LG, Levin MJ, Ljungman P, et al. “2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host.” Clinical Infectious Diseases, 58(3): e44–e100, 2014. Infectious Diseases Society of America (IDSA). Updated recommendations per CDC/ACIP 2024. ↩︎